Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SMO | Q99835 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3648249 | 0.84 | CTDSP1 (0.61) | RAB9ANPC1SMN1; SMN2SENP7CASP3 | |
| SCHEMBL14809997 | 0.84 | NPC1 (0.60) | RAB9ANPC1SMN1; SMN2SENP7CASP3 | |
| SCHEMBL27741786 | 0.83 | NPC1 (0.72) | RAB9ANPC1SMN1; SMN2SENP7CASP3 | |
| SCHEMBL3644011 | 0.82 | NPC1 (0.58) | RAB9ANPC1SMN1; SMN2SENP7CASP3 | |
| SCHEMBL242627 | 0.80 | CTDSP1 (0.58) | RAB9ANPC1SMN1; SMN2SENP7CASP3 | |
| SCHEMBL6484854 | 0.77 | MAPK14 (0.63) | RAB9ANPC1SMN1; SMN2SENP7CASP3 | |
| SCHEMBL3692357 | 0.77 | MAPK14 (0.52) | RAB9ANPC1SMN1; SMN2SENP7CASP3 | |
| SCHEMBL2963776 | 0.77 | MAPK14 (0.68) | RAB9ANPC1SMN1; SMN2TDP1MAPK14 | |
| SCHEMBL3685018 | 0.77 | SMO (0.80) | MAPK14MAPTSMO | |
| SCHEMBL3687826 | 0.77 | MAPK14 (0.80) | RAB9ANPC1SMN1; SMN2SENP7CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311748-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
| EP-2188255-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | AstraZeneca AB (SE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009027746-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311748-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | SHH, GLI1, HRH4 | RAB9A 1639/4885NPC1 2034/4885SMN1; SMN2 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.